ProFactor Pharma

ProFactor Pharma is a Scotland-based biopharmaceutical company dedicated to improving the accessibility of treatments for Hemophilia A. The company's primary focus is the development of PFP-003, a recombinant Factor VIII (rFVIII) therapy produced using a proprietary high-yield manufacturing process. By leveraging advanced cell line technology, ProFactor Pharma aims to significantly lower the cost of production compared to existing rFVIII products. This cost-advantage strategy is designed to address the significant unmet need in global markets where expensive clotting factors are often unavailable. The company is currently progressing its lead candidate through clinical trials to demonstrate safety and efficacy.